Benjamin P. Linas, MD

Professor, Medicine

Benjamin Linas
617.414.5238

Biography

Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.

Other Positions

  • Associate Professor, Epidemiology, Boston University School of Public Health

Education

  • New York University School of Medicine, MD
  • Harvard School of Public Health, MPH
  • Yale University, BA

Publications

  • Published on 3/21/2022

    Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 Mar 21. PMID: 35315148.

    Read at: PubMed
  • Published on 3/21/2022

    Savinkina A, Madushani RWMA, Eftekhari Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. Addiction. 2022 Mar 21. PMID: 35315162.

    Read at: PubMed
  • Published on 3/12/2022

    Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M, Morgan T, Belperio P, Backus L, Doss W, Esmat G, Hassany M, Elsharkawy A, Elakel W, Mehrez M, Foster GR, Wose Kinge C, Chew KW, Chasela CS, Sanne IM, Thanung YM, Loarec A, Aslam K, Balkan S, Easterbrook PJ, Linas BP. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. J Viral Hepat. 2022 Mar 12. PMID: 35278339.

    Read at: PubMed
  • Published on 3/7/2022

    Lee SS, Weitz M, Ardlie K, Bantham A, Schuckel MF, Goehringer K, Hogue C, Hosking R, Mortimer K, Saadat A, Seaman-Chandler J, Linas BP, Ciaranello A. Resources Required for Implementation of SARS-CoV-2 Screening in Massachusetts K-12 Public Schools in Winter/Spring 2021. J Sch Health. 2022 Mar 07. PMID: 35253219.

    Read at: PubMed
  • Published on 3/1/2022

    Morgan JR, Quinn EK, Chaisson CE, Ciemins E, Stempniewicz N, White LF, Linas BP, Walley AY, LaRochelle MR. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. Med Care. 2022 03 01; 60(3):256-263. PMID: 35026792.

    Read at: PubMed
  • Published on 2/1/2022

    Giardina J, Bilinski A, Fitzpatrick MC, Kendall EA, Linas BP, Salomon J, Ciaranello AL. Model-Estimated Association Between Simulated US Elementary School-Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels. JAMA Netw Open. 2022 02 01; 5(2):e2147827. PMID: 35157056.

    Read at: PubMed
  • Published on 2/1/2022

    Linas BP, Assoumou SA. Laying the Foundation for a New and Inclusive Science. JAMA Netw Open. 2022 02 01; 5(2):e2148540. PMID: 35157061.

    Read at: PubMed
  • Published on 2/1/2022

    Adams JW, Savinkina A, Hudspeth JC, Gai MJ, Jawa R, Marks LR, Linas BP, Hill A, Flood J, Kimmel S, Barocas JA. Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use-Associated Infective Endocarditis. JAMA Netw Open. 2022 02 01; 5(2):e220541. PMID: 35226078.

    Read at: PubMed
  • Published on 1/10/2022

    Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022 04; 7(4):307-317. PMID: 35026142.

    Read at: PubMed
  • Published on 12/15/2021

    Sinha P, Lakshminarayanan SL, Cintron C, Narasimhan PB, Locks LM, Kulatilaka N, Maloomian K, Prakash Babu S, Carwile ME, Liu AF, Horsburgh CR, Acuna-Villaorduna C, Linas BP, Hochberg NS. Nutritional Supplementation Would Be Cost-Effective for Reducing Tuberculosis Incidence and Mortality in India: The Ration Optimization to Impede Tuberculosis (ROTI-TB) model. Clin Infect Dis. 2021 Dec 15. PMID: 34910141.

    Read at: PubMed

View 119 more publications: View full profile at BUMC

View all profiles